ISRCTN80827145
Completed
未知
A randomised, double blind trial to assess the morphological and biological effects with Arimidex, compared to placebo when used as neoadjuvant treatment for patients with endometrial cancer
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Department of Health
- Enrollment
- 170
- Status
- Completed
- Last Updated
- 8 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patients for this study will be recruited form a number of selected gynaecology/oncology units in the Yorkshire Strategic Health Authority. No formal power calculation is possible as there is no information or literature in this research. An arbitrary figure of 60 patients has been chosen based on 30% accrual from the patient population. Currently 203 patients per year are registered in the Yorkshire region. Of these, 84%b undergo surgery (n \= 170\) and therefore eligible to participate. In order to produce more information on the Arimimdex arm the patients will be randomised on a 2:1 basis to either Arimidex or placebo.
Exclusion Criteria
- •Does not meet inclusion criteria
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not yet recruiting
Phase 1
Sodium in adults and Adolescents Lowering Trial: the SALT trialCirculatory SystemNutritional, Metabolic, EndocrinePACTR202306727520808MRC Wits Developmental Pathways for Health Research Unit1,500
Completed
Not Applicable
Double blinded evaluation of the effectiveness of Neuro Psycho Physical Optimization with Conveyer of Modulating Radiance (CMR) in stress-related disorders, assessed with Psychological Stress Measure TestPerception of stress, and stress-related symptoms.Mental Health - Other mental health disordersACTRN12607000529448Istituto Rinaldi Fontani200
Active, not recruiting
Phase 1
Efficacy and Safety of apraglutide in steroid refractory gastrointestinal acute graft versus host diseaseAcute graft versus host disease (GVHD)MedDRA version: 20.0Level: PTClassification code 10075160Term: Graft versus host disease in gastrointestinal tractSystem Organ Class: 10021428 - Immune system disordersMedDRA version: 20.0Level: LLTClassification code 10075161Term: Graft versus host disease in GI tractSystem Organ Class: 10021428 - Immune system disordersMedDRA version: 20.1Level: PTClassification code 10066264Term: Acute graft versus host disease in intestineSystem Organ Class: 10021428 - Immune system disordersMedDRA version: 20.1Level: PTClassification code 10066260Term: Acute graft versus host diseaseSystem Organ Class: 10021428 - Immune system disordersTherapeutic area: Body processes [G] - Immune system processes [G12]EUCTR2021-004588-29-ESVectivBio AG34
Active, not recruiting
Not Applicable
A randomised, double blind study to evaluate the safety and efficacy of the p38 kinase inhibitor, GW856553, in subjects with neuropathic pain from lumbosacral radiculopathyeuropathic pain from lumbosacral radiculopathyMedDRA version: 12.0Level: LLTClassification code 10037779Term: RadiculopathyEUCTR2009-012836-33-DEGlaxoSmithKline Research & Development Limited142
Active, not recruiting
Phase 1
A randomised, double blind study to evaluate the safety andefficacy of the p38 kinase inhibitor, GW856553, in subjects withneuropathic pain from peripheral nerve injury.Estudio aleatorizado, doble ciego para evaluar la seguridad y la eficacia de GW856553, un inhibidor de la quinasa p38, en sujetos con dolor neuropático por lesión de nervio periférico.europathic painMedDRA version: 9.1Level: LLTClassification code 10054095Term: Neuropathic painEUCTR2009-010091-17-ESGlaxoSmithKline Research & Development Limited